A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
← catalyst calendarNCT06952465 · readout in 1,929 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
2,000estimated
Sites
2
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-24 | actual | When the study began enrolling |
| Primary completion | 2031-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psoriasis
Interventions
- Drug: Deucravacitinib
- Biological: Any biologic treatment for psoriasis
Primary outcomes
what the primary-completion date above is the date OFParticipant baseline demographics
measured Baseline
Participant medical history
measured Baseline
Incidence of serious infections
measured Up to 9-years
Incidence of malignancies
measured Up to 9-years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed